BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort Global Opportunities PCC
BBS-Bioactive Bone Substitutes Plc, Company announcement, Inside information, 31 March 2023 at 7.45 p.m. (EEST)
BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort Global Opportunities PCC
BBS-Bioactive Bone Substitutes Plc (“BBS, “Company”) has today renewed the company's capital facility agreement announced on September 30, 2021 with Riverfort Global Opportunities PCC (“RiverFort”) and the maturity dates of repayment installments have been extended by one year. For the first installment the maturity date is 31 March 2024 (previously 31 March 2023) and for the second it is 22 August 2024 (previously 22 August 2024). Key commercial terms and conditions remain unchanged. The reference price on the outstanding amount is recalculated according to the agreement terms to be now EUR 1.008 per share. Consequently, the fixed conversion price shall be EUR 1.4113 per share.
The issuer shall issue 177,140 warrants to Riverfort with the exercise price of EUR 1.4113 per share and expiry date of March 2027.
RiverFort has decided to convert EUR 50,000 of the loan capital into BBS shares, and in addition, a contract renewal fee (5% of the loan capital, equal to EUR 25,000) will be settled in shares. Consequently, BBS issued RiverFort a total of 84,303 company shares at a price of EUR 0.8897 per share. After the transfers, BBS will hold 425,220 treasury shares.
"Our close cooperation with RiverFort continues, and the new arrangement strengthens our company's working capital and supports the company's goal of receiving the CE marking," says Ilkka Kangasniemi, CEO of BBS.
For more information, please contact:
Ilkka Kangasniemi, CEO,+358 40 7080307,
ilkka.kangasniemi@bbs-artebone.fi
Certified Advisor: Nordic Certified Adviser AB,+46 70 551 67 29,
info@certifiedadviser.se
BBS in brief
BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiology company whose core competence is the development, commercialization and manufacture of easy-to-use bone implants that promote bone formation and healing. Bone substitutes, i.e. implants, are intended for the treatment of various bone damage, bone healing problems and bone diseases instead of autologous and bank bone grafts. BBS aims to become one of the leading players in the field of bioactive implants intended for bone healing problems. The company's head office is located in Oulu, and it employs 20 people.
BBS was founded in 2003, and the company has been listed on Nasdaq First North Growth Market Finland since February 2018.
More information: www.bbs-artebone.fi
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Calibre Announces the Publication of its 2022 Sustainability Report, Demonstrating Commitment to Transparency and Responsible Practices6.6.2023 12:00:55 CEST | Press release
VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) is pleased to announce the publication of its 2022 Sustainability Report (“the Report”). The Report outlines Calibre’s 2022 progress and achievements, provides guidance for the Company’s Environmental, Social and Governance (“ESG”) performance, and underscores Calibre’s unwavering commitment to transparency, accountability and responsible business practices. Calibre acknowledges that incorporating sustainability into its business strategy is essential to our long-term success. In 2022, the Company saw record production for the third consecutive year. Calibre’s increasing focus on sustainability practices and robust ESG performance ensures that such accomplishments are achieved in ways that are ethical, transparent, accountable, and respectful of the rights of others. Darren Hall, President and Chief Executive Officer, stated: “At Calibre, we recogniz
Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award6.6.2023 12:00:00 CEST | Press release
WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building. Dr. Monath was selected for the Gold Medal for his more than four decades of commitment to advancing knowledge of arboviruses and vaccine research and development (R&D) that contributed to the development of several innovative vaccines including those for Ebola Zaire, smallpox, dengue, Japanese encephalitis and West Nile. The Gold Medal, celebrating three decades of recognition, is Sabin’s highest scientific honor. It is given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Bill Foege, Anne
PRESS RELEASE: SSH launches OpenSSH support service for multi-platform SSH environments6.6.2023 12:00:00 CEST | Press release
Helsinki, Finland - June 6, 2023 - To resolve various customer support problems regarding OpenSSH implementations, SSH has launched a support service for OpenSSH. As a result, customers benefit from high-quality SSH support services also for the open-source variant of SSH software. OpenSSH will be supported on Windows and Red Hat Linux platforms. The SSH protocol is a secure network protocol used to establish encrypted and secure remote connections and transfer data between different systems. OpenSSH is an open-source implementation of the SSH protocol. It was initially released as a free version of SSH’s Tectia product. As an open-source product, OpenSSH is popular, especially as SSH client software. However, its usage in critical corporate environments has been partly limited due to a lack of high-quality support services or support from a single source for all SSH clients. Without proper support services, customers often invest in in-house OpenSSH expertise, resulting in increased o
Novo Nordisk A/S – Share repurchase programme6.6.2023 11:56:26 CEST | Press release
Bagsværd, Denmark, 6June 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 August 2023. Since the announcement 30 May of the programme, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement906,0001,042,810,01330 May 202382,7001,123.3192,897,99931 May 202385,0001,117.9295,023,0001 June 202385,0001,109.7994,332,2702 June 202390,0001,076.5596,889,206Accumulated under the
Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares6.6.2023 11:39:07 CEST | Press release
Company announcement no. 23 - 23 6 June 2023 Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares In accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), NTG Nordic Transport Group A/S (“NTG”), CVR no. 12546106, hereby announces receipt of the following notification from persons discharging managerial responsibilities in NTG, and persons closely associated with them, in NTG's shares and other financial instruments linked thereto: Eivind Drachmann Kolding (Chairman of the Board of Directors) Eivind Drachmann Kolding, Chairman of the Board of Directors of NTG, has on 2 June 2023 sold a total of 8,900 shares in NTG of nominally DKK 20 each at a price of DKK 439.63 per share. Reference is made to the attached notification. Additional information For additional information, please contact: Inves